- Home
- ATGE vs PTCT Comparison
ATGE vs PTCT Comparison
Compare ATGE & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- PTCT
- Stock Information
- Founded
- ATGE 1987
- PTCT 1998
- Country
- ATGE United States
- PTCT United States
- Employees
- ATGE N/A
- PTCT N/A
- Industry
- ATGE Other Consumer Services
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- ATGE Consumer Discretionary
- PTCT Health Care
- Exchange
- ATGE Nasdaq
- PTCT Nasdaq
- Market Cap
- ATGE 4.4B
- PTCT 3.9B
- IPO Year
- ATGE 1991
- PTCT 2013
- Fundamental
- Price
- ATGE $121.51
- PTCT $49.15
- Analyst Decision
- ATGE Strong Buy
- PTCT Buy
- Analyst Count
- ATGE 3
- PTCT 14
- Target Price
- ATGE $135.67
- PTCT $63.57
- AVG Volume (30 Days)
- ATGE 453.2K
- PTCT 1.1M
- Earning Date
- ATGE 08-05-2025
- PTCT 08-07-2025
- Dividend Yield
- ATGE N/A
- PTCT N/A
- EPS Growth
- ATGE 129.73
- PTCT N/A
- EPS
- ATGE 6.03
- PTCT 7.51
- Revenue
- ATGE $1,741,091,000.00
- PTCT $1,772,758,000.00
- Revenue This Year
- ATGE $14.09
- PTCT $121.50
- Revenue Next Year
- ATGE $6.36
- PTCT N/A
- P/E Ratio
- ATGE $20.23
- PTCT $6.53
- Revenue Growth
- ATGE 13.10
- PTCT 91.12
- 52 Week Low
- ATGE $66.90
- PTCT $29.02
- 52 Week High
- ATGE $140.12
- PTCT $58.38
- Technical
- Relative Strength Index (RSI)
- ATGE 45.09
- PTCT 48.65
- Support Level
- ATGE $120.00
- PTCT $48.18
- Resistance Level
- ATGE $130.40
- PTCT $50.57
- Average True Range (ATR)
- ATGE 4.48
- PTCT 1.58
- MACD
- ATGE -0.37
- PTCT -0.34
- Stochastic Oscillator
- ATGE 32.46
- PTCT 25.67
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.